Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 1/20 | 0.51 |
| ▸ | METAP1 | P53582 | 1/20 | 0.51 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.37 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.36 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.34 |
| ▸ | GRIN2B | Q13224 | 10/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.31 |
| ▸ | PDE5A | O76074 | 1/20 | 0.31 |
| ▸ | GUSB | P08236 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31064848 | 0.75 | SMN1; SMN2 (0.52) | METAP2METAP1NPY5RENPP1GRIN2B | |
| SCHEMBL7787137 | 0.75 | METAP2 (0.47) | METAP2METAP1NPY5RENPP1 | |
| SCHEMBL2011131 | 0.75 | METAP2 (0.47) | METAP2METAP1NPY5RENPP1GRIN2B | |
| SCHEMBL3801779 | 0.75 | METAP2 (0.47) | METAP2METAP1NPY5RENPP1GRIN2B | |
| SCHEMBL5632 | 0.75 | NUDT1 (0.50) | METAP2METAP1NPY5REGFR | |
| SCHEMBL375955 | 0.75 | SMN1; SMN2 (0.52) | METAP2METAP1NPY5RENPP1GRIN2B | |
| SCHEMBL357003 | 0.75 | METAP2 (0.47) | METAP2METAP1NPY5RENPP1GRIN2B | |
| SCHEMBL3894 | 0.75 | METAP2 (0.47) | METAP2METAP1NPY5RENPP1 | |
| SCHEMBL1963575 | 0.75 | METAP2 (0.47) | METAP2METAP1NPY5RENPP1 | |
| SCHEMBL30388675 | 0.75 | NUDT1 (0.50) | METAP2METAP1NPY5REGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 458 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119455413-A | Allopurinol desalination and evaporation device and desalination and evaporation method thereof | 宜兴市星宇药业有限公司 | 2025-02-18 | — | — | CN | claimed |
| CN-119031915-A | Methods and compositions for treating skin proliferative disorders and other skin conditions | 不对称疗法有限责任公司 | 2024-11-26 | — | — | CN | claimed |
| CN-118048204-A | Wafer cleaning liquid for cleaning copper surface after chemical mechanical planarization | 华中科技大学 | 2024-05-17 | — | — | CN | claimed |
| WO-2023202686-A1 | COMPOSITION AND METHOD FOR INHIBITING XANTHINE DEHYDROGENASE (XDH) | 上海舶望制药有限公司 | 2023-10-26 | — | — | WO | claimed |
| CN-115968815-A | Induction method for efficiently producing full-male nibea albiflora triploid | 浙江省海洋水产研究所 | 2023-04-18 | — | — | CN | claimed |
| CN-113416522-A | Low-conductivity anti-freezing cooling liquid for new energy power battery and preparation method thereof | 上海科鸿能源发展有限公司 | 2021-09-21 | — | — | CN | claimed |
| WO-2017062966-A1 | ANTIBODIES SPECIFIC FOR 4,6-DIAMINO-5-(FORMYULAMINO) PYRIMIDINE AND USES THEREOF | FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2017-04-13 | — | — | WO | claimed |
| WO-2013181296-A2 | COMPOSITIONS AND METHODS FOR MANAGING WEIGHT | UNIGEN, INC. (US) | 2013-12-05 | — | — | WO | claimed |
| US-20050026862-A1 | Cosmetic or dermatological preparation | BEIERSDORF AG | 2005-02-03 | — | — | US | claimed |
| EP-1282680-A1 | COMPOSITIONS COMPRISING CYCLODEXTRIN | THE PROCTER & GAMBLE COMPANY (US) | 2003-02-12 | — | — | EP | claimed |
| WO-2001088076-A1 | COMPOSITIONS COMPRISING CYCLODEXTRIN | THE PROCTER & GAMBLE COMPANY (US) | 2001-11-22 | — | — | WO | claimed |
| US-6289286-B1 | Surface regeneration of biosensors and characterization of biomolecules associated therewith | BIACORE AB (SE) | 2001-09-11 | — | — | US | claimed |
| WO-2001060961-A1 | STABLE, AQUEOUS COMPOSITIONS FOR TREATING SURFACES, ESPECIALLY FABRICS | THE PROCTER & GAMBLE COMPANY (US) | 2001-08-23 | — | — | WO | claimed |
| EP-1082607-A1 | SURFACE REGENERATION OF BIOSENSORS | Biacore AB (SE) | 2001-03-14 | — | — | EP | claimed |
| US-6011112-A | SILYLATED ORGANONITROGEN COMPOUNDS | WACKER-CHEMIE GMBH (DE) | 2000-01-04 | — | — | US | claimed |
| WO-1999063333-A1 | SURFACE REGENERATION OF BIOSENSORS | BIACORE AB (SE) | 1999-12-09 | — | — | WO | claimed |
| EP-0852606-B1 | ORGANOPOLYSILOXANE COMPOUNDS CROSS-LINKABLE BY CLEAVING OF ALCOHOLS TO FORM ELASTOMERS | WACKER CHEMIE GMBH (DE) | 1999-04-14 | — | — | EP | claimed |
| EP-0634927-A1 | TREATMENT AND PROPHYLAXIS OF DISEASES CAUSED BY PARASITES, OR BACTERIA | STATENS SERUMINSTITUT (DK) | 1995-01-25 | — | — | EP | claimed |
| US-5321032-A | Peptide compounds and pharmaceutical compositions thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1994-06-14 | — | — | US | claimed |
| WO-1993017671-A1 | TREATMENT AND PROPHYLAXIS OF DISEASES CAUSED BY PARASITES, OR BACTERIA | STATENS SERUMINSTITUT (DK) | 1993-09-16 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050026862-A1 | Cosmetic or dermatological preparation | OGG1, UNG, MPG | METAP2 1389/4885METAP1 1594/4885NPY5R 1895/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.